newsfilter
← Latest News
PR Newswire·

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and consistent clinical relevanceFirst Phase 3 evidence to